STOCK TITAN
  1. Home
  2. News
  3. ORTX

Orchard Therapeutics Plc - ORTX STOCK NEWS

Welcome to our dedicated page for Orchard Therapeutics Plc news (Ticker: ORTX), a resource for investors and traders seeking the latest updates and insights on Orchard Therapeutics Plc stock.

Orchard Therapeutics Plc (ORTX) delivers groundbreaking gene therapies for rare inherited disorders, focusing on transformative treatments for pediatric patients. This page provides centralized access to all official company announcements, regulatory filings, and clinical development updates.

Investors and researchers will find timely information on clinical trial progress, regulatory milestones, and strategic partnerships shaping the future of gene-based medicine. The curated news collection spans therapy approvals, research collaborations with leading institutions, and manufacturing advancements critical to orphan disease treatment accessibility.

Regular updates ensure stakeholders maintain current awareness of ORTX's innovations in hematopoietic stem cell therapies and neurometabolic disorder treatments. Bookmark this page for efficient tracking of material developments affecting the company's position in the advanced therapies sector.

News

Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments

Rhea-AI Summary
Orchard Therapeutics (Nasdaq: ORTX) reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date. The company announced a planned acquisition by Kyowa Kirin valued at up to $477.6 million, with the U.S. FDA accepting the Biologics License Application for OTL-200 in MLD under Priority Review. Orchard Therapeutics highlighted ten active newborn screening studies globally and presented eight sessions at ESGCT. The company's CEO expressed optimism for the future and provided an overview of the financial results for the quarter ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
earnings
-
News

Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023

Rhea-AI Summary
Orchard Therapeutics announces positive clinical outcomes for gene therapy treatment of MPS-IH
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
-
News

Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023

Rhea-AI Summary
Orchard Therapeutics to present eight presentations at ESGCT Congress showcasing the potential of their HSC gene therapy platform. Data from a study of OTL-203 in MPS-IH shows positive outcomes. CTO Nicoletta Loggia to discuss manufacturing strategies for gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
News

Lifshitz Law PLLC Announces Investigations of SLGC, ORTX, SP

Rhea-AI Summary
Lifshitz Law PLLC announces investigations of SLGC, ORTX, SP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Kyowa Kirin to Acquire Orchard Therapeutics

Rhea-AI Summary
Kyowa Kirin to acquire Orchard Therapeutics for $16.00 per ADS in cash, representing a total maximum equity value of approximately $477.6 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
95.95%
Tags
acquisition
-
News

Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review

Rhea-AI Summary
Orchard Therapeutics announces FDA acceptance of BLA for OTL-200 in MLD with PDUFA date set for March 18, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.61%
Tags
none
News

Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023

Rhea-AI Summary
Orchard Therapeutics announces long-term results of gene therapy for metachromatic leukodystrophy, showing significant improvement in motor function and cognitive preservation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
-
News

Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA

Rhea-AI Summary
Orchard Therapeutics (Nasdaq: ORTX) reported $6.6M in Q2’23 Libmeldy net sales, securing $34.0M of additional capital from second closing of strategic financing. The company identified four MLD patients from ~150,000 newborns screened, suggesting higher incidence than previously estimated. Six presentations at ASGCT showcased HSC gene therapy's potential. The BLA submission for OTL-200 to the FDA is completed, and the company expects acceptance in Q3’23.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
none
-
News

Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
News

Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results

Rhea-AI Summary
Orchard Therapeutics will host a conference call and live webcast on August 3, 2023, to review business updates and its second quarter 2023 financial results. The webcast will be available on the company's website and a replay will be archived.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
conferences earnings
Stock ORTX logo
Orchard Therapeutics Plc

Nasdaq:ORTX

ORTX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ORTX Stock Data

380.11M
20.54M
12.21%
103.6%
0.14%
Biotechnology
Healthcare
Link
United Kingdom
London